Antigen-Binding Domain

An antigen-binding domain which binds prostate-specific membrane antigen (PSMA) and comprises either:

• (a) a heavy chain variable region (VH) having complementarity determining regions (CDRs):
• HCDR1, HCDR2 and HCDR3;
• and a light chain variable region (VL) having CDRs:
• LCDR1, LCDR2 and LCDR3 selected from the following:
• (i) HCDR1—SEQ ID No. 1;
• HCDR2—SEQ ID No. 2;
• HCDR3—SEQ ID No. 3;
• LCDR1—SEQ ID No. 4;
• LCDR2—SEQ ID No. 5;
• LCDR3—SEQ ID No. 6;
• (ii) HCDR1—SEQ ID No. 9;
• HCDR2—SEQ ID No. 10;
• HCDR3—SEQ ID No. 11;
• LCDR1—SEQ ID No. 12;
• LCDR2—SEQ ID No. 13;
• LCDR3—SEQ ID No. 14;
• (iii) HCDR1—SEQ ID No. 17;
• HCDR2—SEQ ID No. 18;
• HCDR3—SEQ ID No. 19;
• LCDR1—SEQ ID No. 20;
• LCDR2—SEQ ID No. 21;
• LCDR3—SEQ ID No. 22;
• (iv) HCDR1—SEQ ID No. 25;
• HCDR2—SEQ ID No. 26;
• HCDR3—SEQ ID No. 27;
• LCDR1—SEQ ID No. 28;
• LCDR2—SEQ ID No. 29;
• LCDR3—SEQ ID No. 30;
• (v) HCDR1—SEQ ID No. 33;
• HCDR2—SEQ ID No. 34;
• HCDR3—SEQ ID No. 35;
• LCDR1—SEQ ID No. 36;
• LCDR2—SEQ ID No. 37;
• LCDR3—SEQ ID No. 38;
• (vi) HCDR1—SEQ ID No. 41;
• HCDR2—SEQ ID No. 42;
• HCDR3—SEQ ID No. 43;
• LCDR1—SEQ ID No. 44;
• LCDR2—SEQ ID No. 45;
• LCDR3—SEQ ID No. 46;
• and
• (vii) HCDR1—SEQ ID No. 49;
• HCDR2—SEQ ID No. 50;
• HCDR3—SEQ ID No. 51;
• LCDR1—SEQ ID No. 52;
• LCDR2—SEQ ID No. 53;
• LCDR3—SEQ ID No. 54;
• or
• (b) a domain antibody variable region having complementarity determining regions (CDRs):
• VHHCDR1, VHHCDR2 and VHHCDR3 selected from the following:
• (i) VHHCDR1—SEQ ID No. 57;
• VHHCDR2—SEQ ID No. 58;
• VHHCDR3—SEQ ID No. 59;
• (ii) VHHCDR1—SEQ ID No. 61;
• VHHCDR2—SEQ ID No. 62;
• VHHCDR3—SEQ ID No. 63;
• (iii) VHHCDR1—SEQ ID No. 65;
• VHHCDR2—SEQ ID No. 66;
• VHHCDR3—SEQ ID No. 67;
• (iv) VHHCDR1—SEQ ID No. 69;
• VHHCDR2—SEQ ID No. 70;
• VHHCDR3—SEQ ID No. 71;
• and
• (v) VHHCDR1—SEQ ID No. 73;
• VHHCDR2—SEQ ID No. 74;
• VHHCDR3—SEQ ID No. 75.